恒瑞医药(01276.HK)：HRS-6093片获国家药监局临床试验批准

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for the clinical trial of HRS-6093 tablets, a novel and selective oral KRAS G12D inhibitor aimed at targeting KRAS G12D mutation proteins for anti-tumor effects [1] Group 1 - The company has announced the approval of a clinical trial for HRS-6093 tablets [1] - HRS-6093 is characterized as a new, efficient, and selective oral KRAS G12D inhibitor [1] - The drug specifically binds to KRAS G12D mutated proteins to exert anti-tumor effects [1]